RxDoctor Payments Data

Jacqueline Fox

Nurse Practitioner · Hyde Park, MANPI 1447875430

Payments from drug & device makers

$5,184in general payments, 2019–2025

Across 180 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$579
  • Novo Nordisk$522
  • Otsuka America Pharmaceutical, Inc.$275
  • Pfizer$166
  • plus $756 from 15 others

What the payments were for

  • Food & beverage$5,184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,184 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$2,159
Medicare patients
31
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol90$77,908
OzempicSemaglutide32$38,107
TradjentaLinagliptin37$24,433
EliquisApixaban23$24,306
JardianceEmpagliflozin18$24,016
TrulicityDulaglutide12$12,503
Atorvastatin Calcium123$1,825
Fluticasone Propionate40$727
Metoprolol Succinate39$726
Pantoprazole Sodium52$717
Albuterol Sulfate HfaAlbuterol Sulfate19$678
Gabapentin13$435
Metformin Hcl52$427
Olmesartan Medoxomil12$416
Losartan Potassium50$405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,712$77,90890 claims
Boehringer IngelheimTradjenta, Jardiance$1,174$48,44955 claims
Novo NordiskOzempic$522$38,10732 claims
PfizerEliquis$166$24,30623 claims
Lilly USA, LLCTrulicity$579$12,50312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Hyde Park

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →